Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Avicatonin [INN]
RN: 103451-84-9
UNII: 7YC47MQN6X
InChIKey: MXBGIICVQSPJBU-UAUXSXORSA-N

Classification Code

  • Reproductive Effect

Molecular Formula

  • C147-H243-N41-O46

Molecular Weight

  • 3322.7935
 
* denotes mobile formatted website

Links to Resources


Search for this InChIKey on the Web

Names and Synonyms

Name of Substance

  • Avicatonin [INN]

Synonyms

  • (Asul,7)-chicken calcitonin
  • Avicatonin
  • CCRIS 7268
  • UNII-7YC47MQN6X

Systematic Names

  • 1,7-Dicarbacalcitonin (chicken), 1-butanoic acid-
  • 1,7-Dicarbacalcitonin (salmon), 1-butanoic acid-2-L-alanine-3-L-serine-26-L-aspartic acid-27-L-valine-29-L-alanine-
  • 1-Butyric acid-2-L-alanine-3-L-serine-7-(L-2-aminobutyric acid)-26-L-aspartic acid-27-L-valine-29-L-alaninecalcitonin (salmon)

Registry Numbers

CAS Registry Number

  • 103451-84-9

FDA UNII

  • 7YC47MQN6X

Other Registry Number

  • 105233-66-7

System Generated Number

  • 0103451849

Structure Descriptors

InChI

1S/C147H245N41O46/c1-23-32-107(199)161-77(18)121(209)178-100(65-189)137(225)173-96(57-73(11)12)133(221)180-102(67-191)138(226)186-115(78(19)192)142(230)164-85(24-2)123(211)183-114(75(15)16)141(229)175-92(53-69(3)4)122(210)158-63-109(201)163-86(33-25-27-48-148)124(212)170-95(56-72(9)10)132(220)179-101(66-190)136(224)168-89(42-45-105(150)197)126(214)166-91(44-47-111(203)204)127(215)172-94(55-71(7)8)131(219)174-97(59-83-61-155-68-160-83)134(222)165-87(34-26-28-49-149)125(213)171-93(54-70(5)6)130(218)167-90(43-46-106(151)198)129(217)185-117(80(21)194)144(232)177-99(58-82-38-40-84(196)41-39-82)145(233)188-52-31-37-104(188)139(227)169-88(35-29-50-156-147(153)154)128(216)184-116(79(20)193)143(231)176-98(60-112(205)206)135(223)182-113(74(13)14)140(228)159-62-108(200)162-76(17)120(208)157-64-110(202)181-118(81(22)195)146(234)187-51-30-36-103(187)119(152)207/h38-41,61,68-81,85-104,113-118,189-196H,23-37,42-60,62-67,148-149H2,1-22H3,(H2,150,197)(H2,151,198)(H2,152,207)(H,155,160)(H,157,208)(H,158,210)(H,159,228)(H,161,199)(H,162,200)(H,163,201)(H,164,230)(H,165,222)(H,166,214)(H,167,218)(H,168,224)(H,169,227)(H,170,212)(H,171,213)(H,172,215)(H,173,225)(H,174,219)(H,175,229)(H,176,231)(H,177,232)(H,178,209)(H,179,220)(H,180,221)(H,181,202)(H,182,223)(H,183,211)(H,184,216)(H,185,217)(H,186,226)(H,203,204)(H,205,206)(H4,153,154,156)/t76-,77-,78+,79+,80+,81+,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,113-,114-,115-,116-,117-,118-/m0/s1

InChIKey

MXBGIICVQSPJBU-UAUXSXORSA-N

Smiles

[H]/N=C(\N)/NCCC[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc3ccc(cc3)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc4cnc[nH]4)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)CCC

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
dog LD50 intramuscular > 10ku/kg (10000iu/kg) LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES

BEHAVIORAL: TREMOR

GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF SALIVARY GLANDS
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 22(Suppl,
mouse LD50 intramuscular > 10ku/kg (10000iu/kg)   Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 22(Suppl,
mouse LD50 intravenous > 10ku/kg (10000iu/kg)   Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 22(Suppl,
mouse LD50 oral > 10ku/kg (10000iu/kg)   Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 22(Suppl,
mouse LD50 subcutaneous > 10ku/kg (10000iu/kg)   Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 22(Suppl,
rat LD50 intramuscular > 10ku/kg (10000iu/kg) BEHAVIORAL: TREMOR Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 22(Suppl,
rat LD50 intravenous > 10ku/kg (10000iu/kg) BEHAVIORAL: MUSCLE WEAKNESS

BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

LUNGS, THORAX, OR RESPIRATION: DYSPNEA
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 22(Suppl,
rat LD50 oral > 10ku/kg (10000iu/kg)   Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 22(Suppl,
rat LD50 subcutaneous > 10ku/kg (10000iu/kg) BEHAVIORAL: MUSCLE WEAKNESS

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 22(Suppl,